Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals (ALNY), a leader in RNAi therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a corporate presentation on June 9, 2025, at 9:20 am ET. Investors and interested parties can access a live audio webcast through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available within 48 hours after the event.
Alnylam Pharmaceuticals (NASDAQ: ALNY) has released its 2024 Corporate Responsibility Report, focusing on "Accepting Challenges to Improve the Health of Humanity." The report showcases significant progress across six corporate responsibility pillars, highlighting environmental stewardship, patient access, and health equity initiatives.
Key achievements include: independently verified data on GHG emissions (Scope 1, 2, and 3), implementation of 100% renewable energy at Norton and Alewife manufacturing sites, advancement of their Patient Access Philosophy, and expansion of the Alnylam Challengers global health equity initiative. The company's culture survey revealed strong employee satisfaction, with 88% of employees feeling accepted and treated fairly.
Alnylam Pharmaceuticals (ALNY), a leader in RNAi therapeutics, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference. The company's management will deliver a corporate overview on Wednesday, May 14, 2025, at 11:20 AM PT (2:20 PM ET). Investors and interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours after the event.
Summary not available.
Alnylam Pharmaceuticals (ALNY) has received a positive CHMP opinion recommending approval of vutrisiran for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) in the EU. This recommendation is based on the successful HELIOS-B Phase 3 study, which met all 10 pre-specified endpoints.
Vutrisiran, marketed as AMVUTTRA®, demonstrated significant reductions in mortality and cardiovascular events while maintaining functional status and quality of life. The treatment offers quarterly subcutaneous dosing and has already received approvals in the U.S. and Brazil in March 2025.
The study showed consistent benefits across all patient subgroups, including those on TTR stabilizers. Safety profile was comparable to placebo, with main reactions including injection site reactions and increases in blood alkaline phosphatase. European Commission's final decision is expected in June 2025.
Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, before U.S. markets open. The company will host a conference call at 8:30 am ET the same day, where management will discuss Q1 2025 performance and future outlook. A live audio webcast will be accessible through the Investors section of Alnylam's website, with an archived version available approximately two hours after the event.
Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference. The company's management will deliver a corporate overview presentation on Tuesday, April 8, 2025, at 11:45 am ET.
Interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours following the event.